Zoledronic acid (Zoledronate)

Catalog No.S1314 Batch:S131403

Print

Technical Data

Formula

C5H10N2O7P2

Molecular Weight 272.09 CAS No. 118072-93-8
Solubility (25°C)* In vitro 0.5MNAOH 6.05 mg/mL (22.23 mM)
DMSO 0.005 mg/mL (0.01 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Zoledronic acid (Zoledronate), a potent osteoclast inhibitor, induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho. Zoledronic acid (ZA) also induces autophagy.
Targets
Rho [1]
(Cell-free assay)
Ras [1]
In vitro

Zoledronic acid (10 µM and 100 µM) causes a significant reduction in the proportions of MCF-7 cells (49.54% and 23.55% of control, respectively) (P < 0.05). Zoledronic acid has little effect on MDA-MB-231 cells at concentrations of 0.1–10 µM, whereas the 100 µM concentration results in a significant reduction in cell number. Zoledronic acid (100 µM) results in a 63.5% reduction in MCF-7 cell number at 72 hours and an 87.1% reduction at 96 hours. Zoledronic acid (10 µM) results in a greater than 4-fold increase in MCF-7 cell apoptosis whereas the 100 µM concentration induces a 6-fold increase in the proportion of apoptotic cells. Zoledronic acid (10 µM) and paclitaxel (2 µM) results in a 5-fold increase in apoptosis (774.8% of control) compared to zoledronic acid alone (155.71%) and a 4-fold increase compared to paclitaxel alone (189.68%). Zoledronic acid-induced apoptosis of MCF-7 breast cancer cells can be inhibited by addition of intermediates of the mevalonate pathway, which is consistent with observations in osteoclasts, macrophages and myeloma cells. [1]

Zoledronic acid enhances OPG gene expression and protein secretion by human osteoblasts (hOB) in a dose-dependent fashion with a maximum effect at 10 nM after 72 hours, consistent with the higher biological potency of Zoledronic acid. Zoledronic acid prevents the inhibitory effects of the glucocorticoid dexamethasone on OPG mRNA and protein production in human osteoblasts. Zoledronic acid induces type I collagen secretion and alkaline phosphatase activity by 2- and 4-fold, respectively, in human osteoblasts. [2]

In vivo

Zoledronic acid (120 mg/kg, s.c.) prevents the formation of lesions, prevents cancellous bone loss and loss of bone mineral density, and reduces osteoclast perimeter in 5T2MM-bearing mice. Zoledronic acid (120 mg/kg, s.c.) also decreases paraprotein concentration, decreases tumor burden, and reduces angiogenesis in 5T2MM-bearing mice. [3]

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    MCF7 cells

  • Concentrations

    100 μM

  • Incubation Time

    72 h

  • Method

    Cells were treated with various concentrations of drug for 72 h.

Animal Study:

[3]

  • Animal Models

    Male C57BL/KaLwRij mice

  • Dosages

    120 µg/kg

  • Administration

    s.c.

Customer Product Validation

Data from [Data independently produced by Liver Int, 2013, 33(1), 127-36]

Data from [Data independently produced by , , J Mol Cell Cardiol, 2016, 99:76-86.]

Selleck's Zoledronic acid (Zoledronate) has been cited by 55 publications

BRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism [ Nat Commun, 2023, 14(1):1413] PubMed: 36918560
BRD9-mediated chromatin remodeling suppresses osteoclastogenesis through negative feedback mechanism [ Nature Communications, 2023, 1413-2023)] PubMed: None
Priming of Colorectal Tumor-Associated Fibroblasts with Zoledronic Acid Conjugated to the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Elicits Anti-Tumor Vδ2 T Lymphocytes [ Cancers (Basel), 2023, 15(3)610] PubMed: 36765569
Priming of Colorectal Tumor-Associated Fibroblasts with Zoledronic Acid Conjugated to the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Elicits Anti-Tumor Vδ2 T Lymphocytes [ Cancers (Basel), 2023, 15(3)610] PubMed: 36765569
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer [ Sci Adv, 2023, 9(18):eadf0108] PubMed: 37134157
Select HDAC Inhibitors Enhance Osteolysis and Bone Metastasis Outgrowth but Can Be Mitigated With Bisphosphonate Therapy [ JBMR Plus, 2023, 7(3):e10694] PubMed: 36936362
Zoledronic Acid Inhibits the Growth of Breast Malignant Phyllodes Tumor by Inducing Mitotic Catastrophe Via the Plk1 Signaling Pathway [ SSRN, 2023, 38 Pages] PubMed: none
Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab [ J Immunother Cancer, 2022, 10(12)e005660] PubMed: 36543375
Label-free metabolic imaging for sensitive and robust monitoring of anti-CD47 immunotherapy response in triple-negative breast cancer [ J Immunother Cancer, 2022, 10-9e005199] PubMed: 36096527
Label-free metabolic imaging for sensitive and robust monitoring of anti-CD47 immunotherapy response in triple-negative breast cancer [ J Immunother Cancer, 2022, 10-9e005199] PubMed: 36096527

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.